Asymptomatic left ventricular dysfunction

被引：0

作者：

Thomas K.G. ^{[1
]}

Redfield M.M. ^{[1
,2
]}

机构：

[1] Mayo Clinic and Foundation, Rochester, MN

[2] Div. Cardiovasc. Dis./Internal Med., Mayo Clinic, Rochester, MN 55905, 200 First Street, SW

来源：

Heart Failure Reviews | 1997年 / 2卷 / 1期

关键词：

Congestive heart failure; Natriuretic peptides; Neurohumoral function; Ventricular dysfunction;

D O I：

10.1023/A:1009763219785

中图分类号：

学科分类号：

摘要：

Increasingly, it is recognized that significant ventricular dysfunction can exist in the absence of symptoms for an extended period of time in patients with cardiovascular disease. Recent multicenter trials have demonstrated that therapy during the asymptomatic phase can reduce progression to symptomatic heart failure and mortality. Little is known about the epidemiology of this problem. However, preliminary studies suggest that the prevalence of asymptomatic left ventricular dysfunction may approach that of clinically apparent congestive heart failure. The mechanisms whereby some patients with severe ventricular dysfunction may remain asymptomatic while others with similar degrees of ventricular dysfunction have severe symptoms of heart failure remain unclear. By understanding these mechanisms, we may devise novel therapies which will prolong the asymptomatic phase and hopefully prevent the progression to heart failure. This review focuses on pertinent clinical and pathophysiologic issues pertaining to asymptomatic left ventricular dysfunction.

引用

页码：11 / 22

页数：11

共 57 条

[1]

Marantz P.R., Tobin J.N., Wassertheil-Smoller S., Steingart R.M., Wexler J.P., Budner N., Lense L., Wachspress J., The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria, Circulation, 77, pp. 607-612, (1988)

[2]

Cohn J.N., The prevention of heart failure - A new agenda, N Engl J Med, 327, pp. 725-727, (1992)

[3]

Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, pp. 1429-1435, (1987)

[4]

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, pp. 293-302, (1991)

[5]

Cohn J.N., Johnson G., Ziesche S., Et al., A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, N Engl J Med, 325, pp. 303-310, (1991)

[6]

Cohn J.N., Archibald D.G., Ziesche S., Et al., Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study, N Engl J Med, 314, pp. 1547-1552, (1986)

[7]

Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, New Engl J Med, 327, pp. 685-691, (1992)

[8]

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 327, pp. 685-691, (1992)

[9]

Pfeffer M.A., Prevention of heart failure and treatment of asymptomatic left ventricular dysfunction, Cardiovascular Therapeutics, (1996)

[10]

Lejemtel T.H., Liang C., Stewart D.K., Et al., Reduced peak aerobic capacity in asymptomatic left ventricular systolic dysfunction - A substudy of SOLVD, Circulation, 90, pp. 2757-2760, (1994)

← 1 2 3 4 5 6 →